Physician profile
Kyle Mccormick
NPI 1801388616
$2,032.30
in general payments reported to CMS, 2019-2025
22 companies · $575 in 2025
The $575 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.67 · 2022: $218 · 2023: $510 · 2024: $715 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,799.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $324.21 | 2022-2025 | |
| Zimmer Biomet Holdings, INC. | $249.80 | 2024-2025 | Comprehensive Shoulder System, Persona |
| Lilly USA, LLC | $234.42 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $193.72 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Depuy Synthes Sales INC. | $145.07 | 2025 | Va-Lcp |
| Phathom Pharmaceuticals, INC. | $143.54 | 2024 | Voquezna |
| Novo Nordisk INC | $139.79 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $107.18 | 2022-2025 | |
| Glaxosmithkline, LLC. | $104.66 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $56.16 | 2023-2025 | Cologuard Collection Kit |
| Harmony Biosciences LLC | $45.16 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.20 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $42.14 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $35.15 | 2023 | Abilify Maintena, Rexulti |
| Tolmar, INC. | $29.60 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $26.61 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
| Inspire Medical Systems, INC. | $22.59 | 2023 | Inspire |
| Sanofi Pasteur INC. | $22.13 | 2022 | |
| Impel Pharmaceuticals INC. | $20.01 | 2023 | Trudhesa |
| Idorsia Pharmaceuticals US INC | $17.69 | 2024 | Quviviq |
| Philips North America LLC | $14.67 | 2021 | |
| Lundbeck LLC | $13.80 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Mccormick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.